A Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL): Combining 90 Yttrium-Zevalin and the Redox-Modulating Agent, Motexafin Gadolinium (MGd)

Trial Profile

A Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL): Combining 90 Yttrium-Zevalin and the Redox-Modulating Agent, Motexafin Gadolinium (MGd)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2011

At a glance

  • Drugs Ibritumomab tiuxetan; Motexafin gadolinium; Rituximab
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Apr 2011 Planned End Date changed from 1 Jan 2011 to 1 Jan 2012. according to ClinicalTrials.gov.
    • 11 Apr 2011 Status changed from completed to active, no longer recruiting, according to ClinicalTrials.gov.
    • 24 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top